Market Newsdesk

ZEELAND, Mich.
, Feb. 27, 2025 /PRNewswire/ — MillerKnoll, a collective of dynamic design brands, has received approval from the Science Based Targets initiative (SBTi) for its near-term science-based emissions reduction targets covering its global activities.

SBTi is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating climate change. They develop standards, tools and guidance which allow companies to set greenhouse gas (GHG) emissions reductions targets in line with what the latest climate science deems necessary to meet the goals of the Paris Agreement.  

“Validating our near-term carbon reduction targets with SBTi is a critical milestone in staying at the forefront of our customers’ expectations for climate action,” said Gabe Wing, Vice President of Sustainability at MillerKnoll. “By aligning with the latest climate science and global standards, we’re ensuring our efforts to enhance the sustainability of our products, spaces, and processes, are credible and impactful.” 

MillerKnoll’s near-term science-based targets as validated by SBTi: 

MillerKnoll commits to reduce absolute scope 1 and 2 GHG emissions 50% by FY2030 from a FY2022 baseline year. MillerKnoll also commits to increase active annual sourcing of renewable electricity from 38.3% in FY2022 to 100% by FY2030. MillerKnoll further commits to reduce absolute scope 3 GHG emissions from purchased goods and services, waste generated in operations and end-of-life treatment of sold products 25% within the same timeframe. 

This achievement, which comes on the heels of MillerKnoll announcing its new sustainability strategy, builds upon the company’s history of environmental stewardship and underscores its ongoing commitment to design for the good of humankind. 

For more information about MillerKnoll’s commitment to sustainability, please visit millerknoll.com/environmental-social-impact/sustainability. 

About SBTi 

The SBTi defines and promotes best practice in science-based target setting and independently assesses companies’ targets. The SBTi is incorporated as a charity, with a subsidiary which will host the target validation services. Their partners are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). To learn more, visit www.sciencebasedtargets.org. 

About MillerKnoll

MillerKnoll is a collective of dynamic brands that comes together to design the world we live in. The MillerKnoll brand portfolio includes Herman Miller, Knoll, Colebrook Bosson Saunders, DatesWeiser, Design Within Reach, Edelman, Geiger, HAY, HOLLY HUNT, Knoll Textiles, Maharam, Muuto, NaughtOne, and Spinneybeck|FilzFelt. MillerKnoll is an unparalleled platform that redefines modern for the 21st century by building a more sustainable, equitable, and beautiful future for all.    

View original content to download multimedia:https://www.prnewswire.com/news-releases/millerknoll-achieves-sbti-validation-for-near-term-carbon-reduction-targets-302387595.html

SOURCE MillerKnoll

PHILADELPHIA and OAKS, Pa., Feb. 27, 2025 /PRNewswire/ — Aquiline, a private investment firm specializing in financial services and technology, and SEI^® (NASDAQ:SEIC) today announced that the companies have entered into a definitive agreement for Aquiline to acquire SEI’s Family Office Services business. Following the transaction’s close, the business will operate as Archway, capitalizing on the well-known and respected brand of the Archway Platform^SM within the family office market.

SEI’s Family Office Services business delivers technology and outsourced services that connect and power the accounting, investment management, and reporting functions of family offices and family office divisions of financial intermediaries. SEI’s Archway Platform is designed to streamline family office operations and deliver advanced financial reporting for ultra-high-net-worth families. As of Dec. 31, 2024, SEI’s Family Office Services business had $723 billion in assets on the Archway Platform.¹

As part of the transaction, Family Office Services employees in SEI’s Indianapolis, Denver, and Oaks offices, including members of the Family Office Services business’ core leadership team, will transition with the business.

Commenting on the opportunity, Vincenzo La Ruffa, Managing Partner at Aquiline, said:

“The Archway Platform has long been the premier provider of accounting and reporting software solutions to family offices across the country. Its powerful general ledger engine can support the most complex families, and we are excited to further invest and extend the platform. We are delighted to be partnering with SEI, a leader in the financial services industry who has shepherded this business for nearly a decade.”

Sandy Ewing, Head of SEI’s Family Office Services business, added:

“As part of SEI’s broader growth strategy, we’re committed to investing in the areas of our business where we believe we can drive growth, and for more than seven years, we’ve made substantial investments in the solutions and capabilities we deliver for the family office segment. Our talented team has worked tirelessly to build and grow this business, evidenced by its strong reputation in the family office market and our award-winning Archway Platform. We’re proud of their contributions to SEI’s growth, and we could not be more appreciative of their dedication to advancing the technology solutions and delivering best-in-class service for our clients.

“Aquiline is a well-respected investment partner across the financial services industry. With their strategic commitment to transforming the client experience and streamlining complex family office operations, we believe they can accelerate growth and adoption of the Archway Platform across the private wealth landscape.”

The total purchase price is $120 million, and the transaction is expected to close in late second quarter 2025, subject to applicable regulatory approval and other customary closing conditions. Morgan Stanley & Co. LLC served as financial advisor to Aquiline, and Ropes & Gray LLP served as legal counsel to Aquiline. Holland & Knight served as legal counsel to SEI.

¹Assets on platform is not indicative of potential revenue.

About Aquiline
Aquiline Capital Partners LP (“Aquiline”) is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of September 30, 2024, Aquiline has approximately $11.3 billion of assets under management and has deployed approximately $7.0 billion of capital across the firm’s three strategies in private equity, venture, and credit.

For more information about Aquiline, its investment professionals, and its portfolio companies, visit www.aquiline.com.

About SEI^®
SEI (NASDAQ:SEIC) is a leading global provider of financial technology, operations, and asset management services within the financial services industry. SEI tailors its solutions and services to help clients more effectively deploy their capital—whether that’s money, time, or talent—so they can better serve their clients and achieve their growth objectives. As of Dec. 31, 2024, SEI manages, advises, or administers approximately $1.6 trillion in assets. For more information, visit seic.com.

Forward-looking statements

This release contains forward-looking statements within the meaning or the rules and regulations of the United States Securities and Exchange Commission. In some cases, you can identify forward-looking statements by terminology, such as “may,” “will,” “expect,” “believe” and “continue” or “appear.” SEI’s forward-looking statements include its’s current expectations as to:

• its strategic focus;
• the expected closing date of the transaction discussed in this release; and
• the operations and prospects of the business after the closing of the transaction described in this release.

You should not place undue reliance on the forward-looking statements in this release, as they are based on the current beliefs and expectations of SEI’s management and subject to significant risks and uncertainties, many of which are beyond the control of SEI’s management and are subject to change. Although SEI’s management believes the assumptions upon which it bases SEI’s forward-looking statements are reasonable, they could be inaccurate. The risks and uncertainties in connection with such forward-looking statements related to the acquisition include, but are not limited to:

• the occurrence of any event, change or other circumstances that could delay the closing of the proposed acquisition;
• the possibility of non-consummation of the proposed acquisition;
• the failure to satisfy any of the conditions to the proposed acquisition;
• the possibility that a governmental entity may prohibit the consummation of the proposed acquisition or may delay or refuse to grant a necessary regulatory approval in connection with the proposed acquisition.

Some of the additional risks and important factors that could cause actual results to differ from those described in SEI’s forward-looking statements can be found in the “Risk Factors” section of SEI’s Annual Report on Form 10-K for the year ended Dec. 31, 2024, filed with the United States Securities and Exchange Commission.

 

View original content:https://www.prnewswire.com/news-releases/aquiline-to-acquire-seis-family-office-services-business-302387582.html

SOURCE SEI Investments Company

TAMPA, Fla.
, Feb. 27, 2025 /PRNewswire/ — DoubleLine Capital Global Bond Portfolio Manager Bill Campell shares his thinking on trade policy under President Trump, including investment risks and opportunities as a protracted and episodic rollout of tariffs likely whipsaws currency exchange rates against the dollar through much of this year.

Mr. Campbell’s research paper, “Assessing Trump Trade Policy: A Year of Rolling Tariffs, Macro Unknowns and FX Volatility,” can be reached here: https://doubleline.com/wp-content/uploads/Assessing-Trump-Trade-Policy_Campbell_2-2025.pdf 

Mr. Campbell joined DoubleLine in 2013. He heads the firm’s Global Sovereign Debt team and is a Portfolio Manager for the DoubleLine Global Bond Strategy and is a permanent member of the Fixed Income Asset Allocation Committee. He covers developed markets, Central and Eastern Europe, the Middle East and Africa (CEEMEA) and China. Prior to DoubleLine, Mr. Campbell worked for Peridiem Global Investors as a Global Fixed Income Research Analyst and Portfolio Manager. Prior to that, he was with Nuveen Investment Management Co., first as a Quantitative Analyst in the Risk Management and Portfolio Construction Group, then as a Vice President in the Taxable Fixed Income Group. Mr. Campbell also worked at John Hancock Financial as an Investment Analyst. He holds a B.S. in Business Economics and International Business, as well as a B.A. in English, from Pennsylvania State University. Mr. Campbell holds an M.A. in Mathematics, with a focus on Mathematical Finance, from Boston University.

About DoubleLine

DoubleLine Capital LP is an investment adviser registered under the Investment Advisers Act of 1940. DoubleLine’s offices can be reached by telephone at (813) 791-7333 or by email at [email protected]. Media can reach DoubleLine by email at [email protected].

DoubleLine® is a registered trademark of DoubleLine Capital LP.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/doubleline-foresees-a-year-of-fx-volatility-on-rolling-trump-tariffs-302386798.html

SOURCE DoubleLine

USA News Group Commentary


Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC
, Feb. 27, 2025 /PRNewswire/ — USA News GroupNews Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what’s being discussed among oncology experts around the world. Recently, the New York Timesput out a report asking big questions about cancer and its treatments, including about the impact of pollution (including microplastics) on cancer rates, genetic mutations, and inflammation. In the UK, The Guardian reported research showing a need for further studies into air pollution as lung cancer diagnoses are on the rise among never-smokers worldwide. As well, experts are sounding the alarm as colorectal cancer rates have skyrocketed among young people. Another report found that the EU is lagging behind the USA in oncology innovation. Among the innovators working diligently for more breakthroughs, recent developments have come from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Genenta Science SPA (NASDAQ: GNTA), Sellas Life Sciences Group, Inc. (NASDAQ: SLS), and Amgen Inc. (NASDAQ: AMGN).

The article continued: The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC) has launched a global initiative to support new projects aimed at improving cancer detection technologies. According to DelveInsight Business Research, the global cancer therapy market is projected to expand at a compound annual growth rate (CAGR) of 9.12%, reaching an estimated value of $285.96 billion by 2030.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, recently shared data from its GOBLET study at the ASCO GI symposium. Oncolytics’ presentations highlighted pelareorep, an innovative immunotherapy that trains the immune system to target cancer by turning “cold” tumors—typically resistant to treatment—into “hot” tumors that respond better to therapy.

The presentations build upon Oncolytics’ momentum so far in 2025, as the company also recently announced a key regulatory approval clearing a path to advance its promising pancreatic treatment offering (pelareorep in combination with mFOLFIRINOX with or without atezolizumab) in newly diagnosed pancreatic adenocarcinoma (PDAC) patients. Following a positive safety review, Oncolytics Biotech is getting closer to full enrolment of Cohort 5 of the GOBLET study.

At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of 33%, and one patient achieved a remarkable complete response, meaning their cancer became undetectable and remained so for over 15 months. To put this into perspective, similar treatments typically achieve response rates of only 10-24%. This underscores pelareorep’s potential to deliver life-changing results in some of the toughest-to-treat cancers.

“In relapsed anal cancer, the efficacy signal that was initially reported continues to outperform historical control trials with the inclusion of additional patients,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. “Importantly, the complete response we observed previously continued beyond the 12 months initially reported. Together, these results point to a clinically meaningful synergy between pelareorep and checkpoint inhibitors like atezolizumab.”

In pancreatic cancer, pelareorep has also demonstrated strong potential to improve outcomes for patients with this aggressive disease. Oncolytics’ASCO GI presentation featured new safety data showing that pelareorep can be combined with modified FOLFIRINOX, another widely used chemotherapy regimen for patients with pancreatic cancer.

“Our new safety data indicate its ability to also be combined with modified FOLFIRINOX, thus expanding its potential to benefit patients with metastatic pancreatic cancer,” added Dr. Heineman. “We will continue to provide updates on the safety and efficacy of pelareorep-based combination therapy from these cohorts as they become available.”

This builds on prior results from the GOBLET study, where pelareorep, combined with atezolizumab, gemcitabine, and nab-paclitaxel, achieved a 62% objective response rate—more than double historical averages of 25%. These findings were pivotal in earning pelareorep FDAFast Track designation in 2022, highlighting its promise to fill the critical unmet need for more effective pancreatic cancer therapies.

The ability to pair pelareorep with modified FOLFIRINOX represents an important step forward in expanding treatment options for metastatic pancreatic cancer. These results not only highlight pelareorep’s versatility but also its potential to enhance outcomes across multiple standard-of-care therapies.

As Oncolytics Biotech advances its clinical programs and prepares for potential pivotal studies, the growing body of evidence continues to solidify pelareorep as a transformative therapeutic option for patients in desperate need of effective treatments.

CONTINUED… Read this and more news for Oncolytics Biotech at:
  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

In other recent industry developments and happenings in the market include:

Back in December, Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced overall survival (OS) data from two patient cohorts evaluated in a Phase 1b trial with gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in combination with palbociclib and either letrozole or fulvestrant, in patients with HR+, HER2-advanced or metastatic breast cancer. 

The recent study on advanced HR+, HER2- breast cancer looked at overall survival in two groups: patients who had never received treatment (41 people) and those whose cancer worsened despite prior CDK4/6 inhibitor therapy (27 people). For those new to treatment, the median survival was 77.3 months. Meanwhile, patients who had previously been treated with a CDK4/6 inhibitor and received the Phase 3 dose of gedatolisib had a median survival of 33.9 months.

“These results highlight the promising clinical development strategy of simultaneously blocking the ER, CDK4/6, and PAM (PI3K/AKT/mTOR) signaling pathways,” said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. “This approach provided the rationale for our two Phase 3 clinical trials, the ongoing VIKTORIA-1 and planned VIKTORIA-2, which are and will be evaluating this treatment strategy in patients with HR+, HER2- advanced breast cancer in the second- and first-line setting, respectively.”

Genenta Science SPA (NASDAQ: GNTA), a biotech company specializing in cancer-fighting cell therapies, has expanded its partnership with AGC Biologics to boost its production capabilities. The updated agreement gives Genenta exclusive access to a high-quality manufacturing suite in Milan, ensuring its treatments meet strict industry standards. This move aims to improve efficiency and reliability in producing its cell therapy products. Meanwhile, Genenta has launched a Phase 1/2a trial for metastatic renal cell cancer (mRCC) and expects to treat six patients by mid-2025 while continuing its glioblastoma study. The company plans to manufacture 27 personalized drug treatments in 2025.

“Our strengthened partnership with AGC Biologics represents our unwavering commitment to patients participating in our GBM and mRCC trials,” said Pierluigi Paracchi, CEO and Co-founder of Genenta. “This enhanced capacity ensures that we can treat a larger number of patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell-based therapies.”

Sellas Life Sciences Group, Inc. (NASDAQ: SLS), a biotech company developing cancer treatments, recently announced that an independent committee has reviewed interim results from its Phase 3 trial of galinpepimut-S (GPS) for acute myeloid leukemia (AML). The review, triggered after 60 patient deaths, confirmed that the trial can continue as planned, showing early signs of effectiveness. The next and final analysis will occur after 80 patient deaths, expected later this year, to determine GPS’s full potential in treating AML.

“Based on all available data, we believe that GPS could become a transformative treatment option for AML, offering hope to patients with limited choices, especially those with relapsed or refractory disease,” said Angelos Stergiou, MD, ScD hc, President and CEO of SELLAS. “We look forward to completing the trial with the final analysis to be conducted once 80 events are reached.”

Amgen Inc. (NASDAQ: AMGN) recently received FDA approval for its drug LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) to treat adults with a specific type of advanced colorectal cancer (KRAS G12C-mutated mCRC). This approval is based on the Phase 3 CodeBreaK 300 study, which showed that this drug combination significantly improved progression-free survival (how long patients lived without their cancer worsening) compared to standard treatments. Patients taking the higher dose of LUMAKRAS with Vectibix saw a median progression-free survival of 5.6 months versus just 2 months with traditional treatments. The combination also led to a 26% response rate, meaning tumors shrank in some patients, while standard treatments showed no response.

Though the study was not designed to measure overall survival conclusively, the combination therapy showed promising results. Side effects were mostly mild to moderate and included rash, dry skin, diarrhea, and fatigue. KRAS G12C mutations occur in about 3-5% of colorectal cancers, and this approval highlights the importance of biomarker testing to match patients with the right treatments.

“There is an immense need for continued innovation and precision medicine to help address metastatic colorectal cancer,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance. “This new combination approach is an important breakthrough for patients with KRAS G12C-mutated metastatic colorectal cancer, offering a new beneficial treatment option for patients living with this devastating and challenging disease.”

Source:
https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:


USA NEWS GROUP


[email protected]


(604) 265-2873

DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Photo – https://mma.prnewswire.com/media/2629564/Pelareorep_Facts.jpg
Logo – https://mma.prnewswire.com/media/2603685/5189450/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncology-breakthroughs-how-cancer-research-is-advancing-in-2025-302387573.html

SOURCE USA News Group